Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883).
Hauke J, Harter P, Ernst C, Burges A, Schmidt S, Reuss A, Borde J, De Gregorio N, Dietrich D, El-Balat A, Kayali M, Gevensleben H, Hilpert F, Altmüller J, Heimbach A, Meier W, Schoemig-Markiefka B, Thiele H, Kimmig R, Nürnberg P, Kast K, Richters L, Sehouli J, Schmutzler RK, Hahnen E. Hauke J, et al. Among authors: kimmig r. J Med Genet. 2022 Mar;59(3):248-252. doi: 10.1136/jmedgenet-2020-107353. Epub 2020 Dec 3. J Med Genet. 2022. PMID: 33273034 Free PMC article.
Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, du Bois A; AGO-OVAR. Wimberger P, et al. Among authors: kimmig r. Gynecol Oncol. 2006 Feb;100(2):300-7. doi: 10.1016/j.ygyno.2005.08.029. Epub 2005 Sep 29. Gynecol Oncol. 2006. PMID: 16199079 Clinical Trial.
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. du Bois A, et al. Among authors: kimmig r. Ann Oncol. 2006 Jan;17(1):93-6. doi: 10.1093/annonc/mdj032. Epub 2005 Nov 9. Ann Oncol. 2006. PMID: 16282248 Free article. Clinical Trial.
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Wimberger P, et al. Among authors: kimmig r. Gynecol Oncol. 2007 Jul;106(1):69-74. doi: 10.1016/j.ygyno.2007.02.026. Epub 2007 Mar 29. Gynecol Oncol. 2007. PMID: 17397910 Clinical Trial.
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Meier W, et al. Among authors: kimmig r. Gynecol Oncol. 2009 Aug;114(2):199-205. doi: 10.1016/j.ygyno.2009.04.026. Epub 2009 May 14. Gynecol Oncol. 2009. PMID: 19446314 Clinical Trial.
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A. Wimberger P, et al. Among authors: kimmig r. Ann Surg Oncol. 2010 Jun;17(6):1642-8. doi: 10.1245/s10434-010-0964-9. Epub 2010 Feb 18. Ann Surg Oncol. 2010. PMID: 20165986
Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy.
Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, Kimmig R, Kasimir-Bauer S. Kuhlmann JD, et al. Among authors: kimmig r. Genes Chromosomes Cancer. 2011 Aug;50(8):598-605. doi: 10.1002/gcc.20882. Epub 2011 May 11. Genes Chromosomes Cancer. 2011. PMID: 21563231
381 results